|

Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System

RECRUITINGSponsored by China-Japan Friendship Hospital
Actively Recruiting
SponsorChina-Japan Friendship Hospital
Started2026-01-19
Est. completion2027-12-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07509775

Summary

This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis
* age between 18 and 75 years
* sign informed consent.

Exclusion Criteria:

* diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)
* pregnancy or lactation
* comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy
* spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis
* unable to provide data due to mental, language, or similar factors.

Conditions2

Ankylosing Spondylitis (AS)Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.